Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Interventional pulmonology use of cell-free DNA assay for metastatic non-small cell lung cancer: the UC Davis experience.

Therapeutic advances in respiratory disease - 1 Jan 2000

Phan Chinh, Jespersen Forrest, Weipert Caroline, Li Tianhong, Yoneda Ken Y

Abstract excerpt

BACKGROUND: Interventional pulmonologists (IPs) are often the first specialist to see patients with suspected metastatic non-small cell lung cancer (mNSCLC). Consequently, they are potentially ideally positioned to expedite the identification of actionable molecular mutations by ordering blood-based cell-free DNA (cfDNA), prior to or upon tissue diagnosis of mNSCLC. METHODS: Retrospective review of cfDNA ordered...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Cell-Free Nucleic Acids

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Source

Open in PubMed Open full text

Identifiers

PMID: 36346075
DOI: 10.1177/17534666221135324
PMCID: PMC9647290

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 11 closest

Interventional pulmonology use of cell-free DNA assay for metastatic non-small cell lung cancer: the UC Davis experience.PMID 36346075Read ↗

Enhanced detection of actionable mutations in NSCLC through pleural effusion cell-free DNA sequencing: A prospective studySemantic proximity Read ↗

Liquid biopsy of fine-needle aspiration supernatant for lung cancer genotyping.Semantic proximity Read ↗

Clinical Utility of Liquid Diagnostic Platforms in Non-Small Cell Lung Cancer.Semantic proximity Read ↗

Pleural effusion supernatant: a reliable resource for cell-free DNA in molecular testing of lung cancer.Semantic proximity Read ↗

Clonal Hematopoiesis: A New Layer in the Liquid Biopsy Story in Lung Cancer.Semantic proximity Read ↗

EGFR mutation testing on plasma and urine samples: A pilot study evaluating the value of liquid biopsy in lung cancer diagnosis and management.Semantic proximity Read ↗

Molecular testing patterns in metastatic non-small cell lung cancer.Semantic proximity Read ↗

Molecular Testing of Non-Small Cell Lung Carcinoma Diagnosed by Endobronchial Ultrasound-Guided Transbronchial Fine-Needle Aspiration: The Cleveland Clinic Experience.Semantic proximity Read ↗

Plasma cfDNA Genotyping in Hospitalized Patients With Suspected Metastatic NSCLC.Semantic proximity Read ↗

Molecular markers in lung cancer: role of EBUS.Semantic proximity Read ↗

CSF cell-free DNA EGFR testing using DdPCR holds promise over conventional modalities for diagnosing leptomeningeal involvement in patients with non-small cell lung cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.